GRANZYME INHIBITION
 viDA has developed a library of proprietary GzmB inhibitors designed to block the pathological activity of GzmB for the treatment of chronic inflammatory and age related diseases in dermatology, musculoskeletal, cardiovascular and pulmonary.  Anticipated clinical benefits of directly inhibiting GzmB activity include: Development of Granzyme Inhibitors

• Advanced tissue healing and improved tissue remodeling:    viDA believes that GzmB is a key factor for the progression of connective tissue damage due to dysregulated inflammation. GzmB inhibitionwill represent a first-in-class therapy that will provide  significant tissue healing and remodeling benefits resulting in a high quality wound heal with greater tensile strength. Research demonstrates that a GzmB inhibitor therapeutic approach has the potential to address multiple pathogenic processes involved in tissue damage due to dysregulated inflammation, including non-healing skin ulcers, photoaging, and vascular injury.

 

• Increased tensile strength of healing tissue:    viDA’s preclinical research has demonstrated that GzmB inhibition to improves the tensile strength of healed tissues.  Inhibition of extracellular GzmB protects the proteoglycan decorin from degradationthereby allowing proper collagen fibrillogenesis to ensue resulting in greater tensile strength of the healed tissue.

 

• Reduced scarring:    Preclinical research suggests that inhibiting extracellular GzmB activity using select inhibitors from viDA’s proprietary library reduces hypertrophic scarring..

 

• Reduced inflammation:    viDA’s proprietary library of GzmB inhibitors represents a unique approach to  treat  chronic inflammatory diseases by preventing the degradation by GzmB of key substrates that make up or reside in the ECM. By preventing degradation, substrate fragments, that unto themselves are bioactive, and sequestered proinflammatory factors are not released into the extracellular milieu.

 

• No immunocompromisation:    Studies using inhibitors and knockout approaches demonstrate that extracellular GzmB inhibition does not suppress immunity.